Posted by Michael Wonder on 09 Mar 2021
AltruBio’s neihulizumab granted fast track designation by the FDA for steroid refractory acute graft versus host disease
8 March 2021 - AltruBio announced today that the U.S. FDA granted fast track designation for its immune checkpoint regulator, neihulizumab for steroid refractory acute graft versus host disease.
Neihulizumab previously received orphan drug designation from the FDA for the treatment of acute graft versus host disease.
Neihulizumab is an immune checkpoint regulator targeting PSGL-1, triggering the depletion of chronically activated T cells.
